Amelioration effects of the soybean lecithin-gallic acid complex on iron-overload-induced oxidative stress and liver damage in C57BL/6J mice

• Published in: Pharmaceutical biology Vol. 61; no. 1; pp. 37 - 49
• Main Authors: Wu, Caihong, Zhang, Wenxin, Yan, Feifei, Dai, Wenwen, Fang, Fang, Gao, Yanli, Cui, Weiwei
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 31.12.2023; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: absorbance; Alanine transaminase; Animals; antioxidant activity; Antioxidants; Antioxidants - therapeutic use; Aspartate transaminase; Bioavailability; Biological Sciences; blood serum; Cholesterol; Deferoxamine; Deferoxamine - metabolism; Deferoxamine - pharmacology; Deferoxamine - therapeutic use; Drug delivery; drugs; excessive iron; Ferritin; Free radicals; Gallic acid; Gallic Acid - pharmacology; gamma-glutamyltransferase; Glutathione; Glycine max; hepatic damage; histopathology; Iron; Iron - metabolism; Iron Overload - drug therapy; Iron Overload - metabolism; Iron Overload - pathology; Lecithin; lecithins; Lecithins - metabolism; Lecithins - pharmacology; Lecithins - therapeutic use; Lipid Peroxidation; Liver; Liver Diseases - drug therapy; malondialdehyde; medicine; Mice; Mice, Inbred C57BL; Oxidative Stress; Phenolic acid; Photometry; soybeans; superoxide dismutase; transferrin receptors; triacylglycerols; excessive iron; hepatic damage; Phenolic acid; antioxidant activity
• ISSN: 1388-0209; 1744-5116; 1744-5116
• DOI: 10.1080/13880209.2022.2151632

Gallic acid (GA) and lecithin showed important roles in antioxidant and drug delivery, respectively. A complex synthesized from GA and soybean lecithin (SL-GAC), significantly improved bioavailability of GA and pharmacological activities. However, the antioxidant activity of SL-GAC and its effect on iron-overload-induced liver injury remains unexplored. This study investigates the antioxidant properties of SL-GAC in vitro and in mice, and its remediating effects against liver injury by iron-overloaded. In vitro, free radical scavenging activity, lipid peroxidation inhibition, and ferric reducing power of SL-GAC were measured by absorbance photometry. In vivo, C57BL/6J mice were randomized into 4 groups: control, iron-overloaded, iron-overloaded + deferoxamine, and iron-overloaded + SL-GAC. Treatments with deferoxamine (150 mg/kg/intraperitioneally) and SL-GAC (200 mg/kg/orally) were given to the desired groups for 12 weeks, daily. Iron levels, oxidative stress, and biochemical parameters were determined by histopathological examination and molecular biological techniques. In vitro, SL-GAC showed DPPH and ABTS free radicals scavenging activity with IC 50 values equal to 24.92 and 128.36 μg/mL, respectively. In C57BL/6J mice, SL-GAC significantly reduced the levels of serum iron (22.82%), liver iron (50.29%), aspartate transaminase (25.97%), alanine transaminase (38.07%), gamma glutamyl transferase (42.11%), malondialdehyde (19.82%), total cholesterol (45.96%), triglyceride (34.90%), ferritin light chain (18.51%) and transferrin receptor (27.39%), while up-regulated the levels of superoxide dismutase (24.69%), and glutathione (11.91%). These findings encourage the use of SL-GAC to treat liver injury induced by iron-overloaded. Further in vivo and in vitro studies are needed to validate its potential in clinical medicine.